Q5117 Injection., kanjinti, 10 milligrams
Also known as: Kanjinti injection, trastuzumab-anns
Injection of Kanjinti, trastuzumab-anns biosimilar per 10 milligrams, a HER2-antagonist antibody.
In Plain Language
HER2 targeted therapy; breast cancer drug
Clinical Context
Used for HER2-positive breast cancer and metastatic gastric cancer therapy.
RVU Information
CPT Q5117 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5117?
CPT Q5117 (Injection., kanjinti, 10 milligrams) is a Q Codes code. Injection of Kanjinti, trastuzumab-anns biosimilar per 10 milligrams, a HER2-antagonist antibody.
Is Q5117 covered by insurance?
Q5117 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for HER2-positive breast cancer and metastatic gastric cancer therapy.
When is CPT Q5117 used?
Used for HER2-positive breast cancer and metastatic gastric cancer therapy.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.